ALK and incontinentia pigmenti: Pulmonary toxicity in patients taking ALK-TKIs has been reported to be relatively rare, with incidence rates of 1.8%, 1.1%, and 2.6% for crizotinib, ceritinib, and alectinib, respectively, regardless of the coexistence of IP [40].